Shanghai Zhangjiang Biotechnology Limited Company

Quick facts

Phase 2 pipeline

• CMAB009 plus Irinotecan · Oncology
  CMAB009 is a PD-1 inhibitor, and Irinotecan is a topoisomerase I inhibitor.
• Irinotecan-only and sequential-CMAB009

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Zhangjiang Biotechnology Limited Company portfolio CI brief
• Shanghai Zhangjiang Biotechnology Limited Company pipeline updates RSS

Related

• Sector hub: All tracked pharma companies